Pharmacokinetics of new antiepileptic drugs

Epilepsia

Volumn 37, Issue SUPPL. 6, 1996, Pages

  Gram, Lennart ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Anticonvulsants; Drug interactions; Drug monitoring; Drug therapy; Drug toxicity; Epilepsy; Felbamate; Gabapentin; Half lives; Lamotrigine; Oxcarbazepine; Pharmacokinetics; Polytherapy; Tia gabine; Topiramate; Vigabatrin

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450; GABAPENTIN; LAMOTRIGINE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; TIAGABINE; TOPIRAMATE; VIGABATRIN;

ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; CONFERENCE PAPER; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; ENZYME ACTIVATION; EPILEPSY; HUMAN; PRIORITY JOURNAL;

EID: 0029803697     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1996.tb06034.x     Document Type: Conference Paper

References (56)

1. Cramer J, Mattson RH, Prevey ML, Scheyer R, Oulette V. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3273-7.
2. Anderson GD, Graves NM. Drug interactions with antiepileptic agents: prevention and management. CNS Drugs 1994;2:268-79.
3. Bialer M. Comparative pharmacokinetics of newer antiepileptic drugs. Clin Pharmacokinet 1993;24:441-52.
4. Perucca E. The clinical pharmacology of the new antiepileptic drugs. Pharmacol Res 1993;28:89-106.
5. Perucca E, Pisani F. Pharmacokinetics and interactions of the new antiepileptic drugs. Epilepsy Res Suppl 1991;3:79-88.
6. Leppik IE, Wolff DL. The place of felbamate in the treatment of epilepsy. CNS Drugs 1995;4:294-301.
7. Wilensky AJ, Friel PN, Ojemann LM, Kupferberg HJ, Levy RH. Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. Epilepsia 1985;26:602-6.
8. Palmer KJ, McTavish D. Felbamate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. Drugs 1993;45:1041-65.
9. Sachdeo R, Kramer LD, Rosenberg A, Sachdeo S. Felba- mate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol 1992;32:386-92.
10. Faught E, Sachdeo RC, Remler MP, et al. Felbamate monotherapy for partial-onset seizures and active-control trial. Neurology 1993;43:688-92.
11. Bourgeois B, Leppik IE, Sadkellares JC, et al. Felbamate: a double-blind controlled trial in patients undergoing presurgical evaluation of partial seizures. Arch Neurol 1993;43:693-6.
12. Richens A. Clinical pharmacokinetics of gabapentin. In: Chadwick D, ed. New trends in epilepsy management: the role of gabapentin. London: Royal Society of Medicine Services, 1993:41-6.
13. Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 1993;10:276-81.
14. Bockbrader HN. Clinical pharmacokinetics of gabapentin. Drugs of Today 1995;31:613-9.
15. Vollmer K, von Hodenberg A, Kolle E. Pharmacokinetics and metabolism of gabapentin in rats, dogs and man. Arzneimittelforschung 1986;36:830-9.
16. Yuen WC, Peck AW. Lamotrigine pharmacokinetics: oral and IV infusion in man [Abstract]. Br J Clin Pharmacol 1988;26:242P.
17. Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1987;42:535-41.
18. Ramsay RE, Pellock JM, Garnett WR, et al. Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Res 1991;10:191-200.
19. Binnie CD, van Emde Boas W, Kasteleijn-Nolste Trenite DG, et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 1986;27:248-54.
20. Yau MK, Garnett WR, Wargin WA, Pellock JM. A single dose proportionality and bioequivalence study of lamotrigine in healthy volunteers [Abstract]. Epilepsia 1991;32(suppl 3):8.
21. Mikati MA, Schachter SC, Schomer DL, et al. Long-term tolerability, pharmacokinetics and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. Clin Neuropharmacol 1989;12:312-21.
22. Jawad S, Yuen WC, Peck AW, Hamilton MJ, Oxley JR, Richens A. Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Res 1987;1:194-201.
23. Wolff P. Lamotrigine: preliminary clinical observations on pharmacokinetics and interactions with traditional antiepileptic drugs. J Epilepsy 1992;5:73-9.
24. Warner T, Patsalos PN, Prevett M, Elyas AA, Duncan JS. Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10,11-epoxide. Epilepsy Res 1992;11:147-50.
25. Schapel GJ, Dollman W, Beran RG, Dunagan FM. No effect of lamotrigine on carbamazepine and carbamazepineepoxide concentrations. Epilepsia 1991;32(suppl 1):58.
26. Pisani F, Russo M, Trio R, et al. Lamotrigine in refractory epilepsy: a long-term open study. Epilepsy Res Suppl 1991;3:187-91.
27. Schütz H, Feldmann KF, Faigle JW, Kriemler HP, Winkler T. The metabolism of 14C-oxcarbazepine in man. Xenobiotica 1986;16:769-78.
28. Kristensen O, Klitgård NA, Jönsson B, Sindrup E. Pharmacokinetics of 10-OH-carbazepine, the main metabolite of the antiepileptic oxcarbazepine, from serum and saliva concentrations. Acta Neurol Scand 1983;68:145-50.
29. Dickinson RG, Hooper WD, Dunstan PR, Eadie MJ. First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite. Eur J Clin Pharmacol 1989;37:69-74.
30. Faigle JW, Menge GP. Pharmacokinetics and metabolic fea- turess of oxcarbazepine and their clinical significance: comparing with carbamazepine. Int Clin Psychopharmacol 1990;5(suppl 1):73-82.
31. Dam M, Ekberg R, Lyning Y, Waltimo O, Jakoben K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed previously untreated epilepsy. Epilepsy Res 1989;3:70-6.
32. Keränen T, Jolkkonen J, Jensen PK, Menge GP, Anderson P. Absence of interactions between oxcarbazepine and erythromycin. Acta Neurol Scand 1992;86:120-31.
33. Mogensen PH, Jørgensen L, Boas J, et al. Effects of dextropropoxyphene on the steady-state kinetics of oxcarbazepine and its metabolites. Acta Neurol Scand 1992;85:14-7.
34. Keränen T, Jolkkonen J, Jensen PK. Single-dose pharmacokinetics of oxcarbazepine after treatment with cimetidine or erythromycin. Epilepsia 1990;31:641.
35. Krämer G, Tettenbron B, Jensen PK, Menga GP, Stoll KD. Oxcarbazepine does not affect the anticoagulant activity of warfarin. Epilepsia 1992;33:1145-8.
36. Jensen PK, Saano V, Haring P, Svenstrup B, Menge GP. Possible interactions between oxcarbazepine and an oral contraceptive. Epilepsia 1992;33:1149-52.
37. Gustavson LE, Mengel HB. Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. Epilepsia 1995;36:605-11.
38. 14C-tiagabine in humans. Epilepsia 1992;33(suppl 3):83.
39. Gustavson LE, Mengel HB, Pierce MW, Chu S-Y. Tiagabine, a new gamma-aminobutyric acid uptake inhibitor antiepileptic drug: pharmacokinetics after single oral doses in man. Epilepsia 1990;31:642.
40. Richens A, Gustavson LE, McKelvy JF, Mengel H, Deadon R, Pierce MW. Pharmacokinetics and safety of single-dose tiagabine HCl in epileptic patients chronically treated with four other antiepileptic drug regimens. Epilepsia 1991;32 (suppl 1):12.
41. Mengel HB, Houston A, Back DJ, Tiagabine: evaluation of the risk of interaction with the oral contraceptive pill in female volunteers. Epilepsia 1993;34(suppl 2):157.
42. Pierce MW, Suzdak ÅD, Gustavson LE, Mengel HB, McKelvy JF, Mant T. Tiagabine. Epilepsy Res Suppl 1991;3:157-60.
43. Easterling DE, Zakszewski T, Moyer MD, Margul BL, Marriott TB, Nayak RK. Plasma pharmacokinetics of topiramate, a new anticonvulsant in humans. Epilepsia 1988;29:662.
44. Doose DR, Scott VV, Margul BL, Marriott TB, Nayak RK. Multiple-dose pharmacokinetics of topiramate in healthy male subjects. Epilepsia 1988;29:662.
45. Doose DR, Walker SA, Sachdeo R, Kramer LD, Nayak RK. Steady-state pharmacokinetics of Tegretol (carbamazepine) and Topamax (topiramate) in patients on monotherapy, and during combined therapy. Epilepsia 1994;35(suppl 8):54.
46. Doose DR, Walker SA, Pledger G, Lim P, Reife RA. Evaluation of phenobarbital and primidone/phenobarbital (primidone's active metabolite) plasma concentrations during administration of add-on topiramate therapy in five multi-center, double-blind, placebo-controlled trials in outpatients with partial seizures. Epilepsia 1995;36(suppl 3):S158.
47. Giscoin LG, Curtin CR, Kramer LD. The steady-state (SS) pharmacokinetics (PK) of phenytoin (Dilantin) and topiramate (Topamax) in epileptic patients on monotherapy and during combination therapy. Epilepsia 1994;35(suppl 8):54.
48. Haegele KD, Schechter PJ. Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S-enantiomer. Clin Pharmacol Ther 1986;40:581-5.
49. Haegele KD, Huebert ND, Ebel M, Tell G, Schechter PJ. Pharmacokinetics of vigabatrin: implications of creatinine clearance. Clin Pharmacol Ther 1988;44:558-65.
50. Cocito L, Maffini M, Perfumo P, Roncallo F, Loeb C. Vi- gabatrin in complex partial seizures: a long-term study. Epilepsy Res 1989;3:160-6.
51. Gram L, Klosterskov P, Dam M. Gamma-vinyl-GABA: a double-blind placebo-controlled trial in partial epilepsy. Ann Neurol 1985;17:262-6.
52. Loiseau P, Hardenberg JP, Pestre M, Guyot M, Schechter PJ, Tell GP. Double-blind, placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy. Epilepsia 1986;27:115-20.
53. Luna D, Dulac O, Pajot N, Beaumont D. Vigabatrin in the treatment of childhood epilepsies: a single-blind placebo-controlled study. Epilepsia 1989;30:430-7.
54. Matilainen R, Pitkänen A, Ruutiainen T, Mervaala E, Sarlund H, Riekkinen P. Effect of vigabatrin on epilepsy in mentally retarded patients: a 7-month follow-up study. Neurology 1988;38:743-7.
55. Rimmer EM, Richens A. Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet 1984;1:189-90.
56. Schechter PJ. Clinical pharmacology of vigabatrin. Br J Clin Pharmacol 1989;27:195-225.